https://www.selleckchem.com/products/Y-27632.html
Current therapies for gastroparesis, metoclopramide and domperidone, carry risks of extrapyramidal symptoms and life-threatening cardiac arrhythmias. Trazpiroben, a novel, potent dopamine D2/D3 receptor antagonist, has low brain permeation and very low affinity for human ether-à-go-go-related gene (hERG) channel inhibition, potentially improving on safety profiles of existing therapies. Trazpiroben demonstrated the following receptor affinities high for D2 and D3, moderate for D4 and minimal for D1 and D5 It demonstrated moderate affini
Like
Comment
Share
